TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28302865

Group type: EXPERIMENTAL
Intervention: Discussion of the diagnosis by trained neurologists with at least two follow-up visits (intervention group)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Discussion of the diagnosis by neurologists and immediate referral to the general practitioner (control group)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study: 25205381

Group type: EXPERIMENTAL
Intervention: Eyes Open (EO) at 0.25 Hz (L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes Open (EO) at 0.50 Hz (H)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes Closed (EC) at 0.25 Hz (L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eyes Closed (EC) at 0.50 Hz (H)
Number of subjects: 10
Study: 22151577

Group type: COMPARATOR
Intervention: Collagen membrane over the osteotomy window (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No membrane (test)
Number of subjects: 18
Study: 22047466

Group type: EXPERIMENTAL
Intervention: Development plan intended to enhance user participation implemented in one hospital.
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group (professionals from two other hospitals).
Number of subjects: 438
Study: 18930568

Group type: COMPARATOR
Intervention: Cilazapril alone (ACE-inhibitor group; n = 30)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Steroid plus cilazapril (combination group; n = 33)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination treatment (hazard ratio, 0.1; 95% CI, 0.014 to 0.946)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Time-average proteinuria (hazard ratio, 14.3; 95% CI, 2.86 to 71.92)
Number of subjects: 63
Study: 16784348

Group type: EXPERIMENTAL
Intervention: High testosterone individuals in low status position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low testosterone individuals in high status position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart rate measurement in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Math test in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone measurement in Study 3
Number of subjects: 0
Study: 15515748

Group type: EXPERIMENTAL
Intervention: 99mTc-ECD SPECT (dynamic)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 99mTc-ECD SPECT (early phase images)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional static 99mTc-ECD SPECT
Number of subjects: 20

Group type: COMPARATOR
Intervention: 133Xe-rCBF SPECT
Number of subjects: 20
Study: 11235580

Group type: EXPERIMENTAL
Intervention: RT plus brachytherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RT plus chemotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RT plus brachytherapy and chemotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 120
Study: 8669235

Group type: EXPERIMENTAL
Intervention: Physical training program of the stomatognathic system for 3 weeks
Number of subjects: 35
Study: 1732926

Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancers detected at prevalence screen, incidence screens, and in the interval between screens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancers detected in those who had refused screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screen-detected invasive cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening procedures
Number of subjects: 0
Study: 6389147

Group type: EXPERIMENTAL
Intervention: 3 mg/kg metoclopramide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg/kg metoclopramide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg/kg metoclopramide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 31731214

Group type: EXPERIMENTAL
Intervention: IVMP with subsequent add-on PLEX
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Simultaneous IVMP and PLEX
Number of subjects: 11
Study: 31357778

Group type: COMPARATOR
Intervention: Entecavir alone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Anluohuaxianwan combined with entecavir
Number of subjects: 219
Study: 28632555

Group type: EXPERIMENTAL
Intervention: Manual Treatment (MT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sham ultrasound treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (LBP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All 3 LBP groups
Number of subjects: 40
Study: 24954745

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg biweekly) and Docetaxel (20 mg/m² weekly) with Radiation Therapy (RT)
Number of subjects: 30
Study: 23595004

Group type: EXPERIMENTAL
Intervention: Beating Heart Problems program (T group; n = 139)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care (C group; n = 136)
Number of subjects: 275
Study: 21858096

Group type: EXPERIMENTAL
Intervention: IPTc with SP and AQ
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1508
Study: 19220513

Group type: EXPERIMENTAL
Intervention: Papilla-base incision (PBI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulcular incision (SI)
Number of subjects: 40
Study: 17852105

Group type: EXPERIMENTAL
Intervention: Surgery for glioblastoma
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Karnofsky score >= 70
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Tumour debulking rather than biopsy
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Right-sided lesion
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Unilateral tumour
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 625
Study: 14747817

Group type: EXPERIMENTAL
Intervention: Intravenous prochlorperazine (0.15 mg/kg; maximum 10 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intravenous ketorolac (0.5 mg/kg; maximum 30 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (prochlorperazine and ketorolac)
Number of subjects: 62
Study: 11870177

Group type: EXPERIMENTAL
Intervention: Four cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m² every 21 days)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Continuous treatment with carboplatin/paclitaxel until progression
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Both arms received second-line weekly paclitaxel at 80 mg/m²/wk after progression
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 230
Study: 10087865

Group type: EXPERIMENTAL
Intervention: Physiological arousal (running in place) with emotional arousal (viewing emotional slide sequence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological arousal (not running in place) with emotional arousal (viewing neutral slide sequence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological arousal (stationary biking) with emotional arousal (viewing emotional slide sequence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued recall task with emotional arousal
Number of subjects: 0
Study: 7738617

Group type: EXPERIMENTAL
Intervention: IFN alpha (3 x 10(6) U/m2) and IL‐2 2.6 x 10(6) IU/m2 (group 1)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: IFN alpha (3 x 10(6) U/m2) and IL‐2 7.8 x 10(6) IU/m2 (group 2)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: IFN alpha (3 x 10(6) U/m2) and IL‐2 11.7 x 10(6) IU/m2 (group 3)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: IFN alpha (6 x 10(6) U/m2) and IL‐2 11.7 x 10(6) IU/m2 (group 4)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: IFN alpha (6 x 10(6) U/m2) and IL‐2 7.8 x 10(6) IU/m2 (group 5)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: IFN alpha (6 x 10(6) U/m2) and IL‐2 15.6 x 10(6) IU/m2 (group 6)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Group 4 (highest dose of IFN alpha three times per day)
Number of subjects: 189
Study: 2073645

Group type: EXPERIMENTAL
Intervention: Alinidine (30 mg 3 times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7441730

Group type: EXPERIMENTAL
Intervention: Subjects who made an overt commitment to return (verbal or verbal plus written agreement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized, no commitment procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects with a known family history of TB
Number of subjects: 0
Study: 6465630

Group type: EXPERIMENTAL
Intervention: 60 mL of 95% ethanol in fruit juice
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 48
Study: 28341910

Group type: EXPERIMENTAL
Intervention: Comprehensive Workers' Health Surveillance (WHS) program
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 305
Study: 26253455

Group type: EXPERIMENTAL
Intervention: Terlipressin (TP) 1.3 μg/kg/h + Norepinephrine (NE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 32
Study: 25126874

Group type: COMPARATOR
Intervention: Timed overnight (8 hours) Urine Albumin (microalbumin) Excretion (UAE)
Number of subjects: 100
Study: 22423604

Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 279

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: MitraClip therapy
Number of subjects: 279
Study: 20376376

Group type: EXPERIMENTAL
Intervention: Artglass composite resin inlays
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Charisma composite resin inlays
Number of subjects: 89

Group type: COMPARATOR
Intervention: Both inlay systems
Number of subjects: 89
Study: 19358456

Group type: EXPERIMENTAL
Intervention: VC start-up 6 dB above NAL-NL1 target
Number of subjects: 22

Group type: COMPARATOR
Intervention: VC start-up 6 dB below NAL-NL1 target
Number of subjects: 22
Study: 15735546

Group type: EXPERIMENTAL
Intervention: HRT administered in patches
Number of subjects: 210

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 210
Study: 12846058

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TEA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10636312

Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) resuscitation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) resuscitation with compression cushion
Number of subjects: 38
Study: 8733848

Group type: EXPERIMENTAL
Intervention: Diffractive bifocal IOL
Number of subjects: 149

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 149
Study: 1756625

Group type: EXPERIMENTAL
Intervention: Stainless steel ring IUD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Copper T 220 IUD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing device (LNG) IUD
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (pre-insertion)
Number of subjects: 90
Study: 6626061

Group type: EXPERIMENTAL
Intervention: Fenoterol powder, 200 mcg three times per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31084264

Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (savings groups for women and peer-groups for men)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (savings groups for women, peer-groups for men, and community leader dialogues)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control Group (savings groups for women, no intervention for men)
Number of subjects: 450
Study: 29910042

Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg bodyweight, intravenous, given at day 0, 14, 28, and then every 4 weeks for a total of seven infusions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26678399

Group type: EXPERIMENTAL
Intervention: Parent‐Adolescent
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Parent‐Only
Number of subjects: 225

Group type: COMPARATOR
Intervention: Self‐Study
Number of subjects: 225

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 225
Study: 24947878

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation program including individualized exercise training (IET), education activities sessions, and dietary management
Number of subjects: 22

Group type: COMPARATOR
Intervention: Education activity sessions
Number of subjects: 22
Study: 22721452

Group type: EXPERIMENTAL
Intervention: Rehabilitation outdoor mobility intervention (up to 12 sessions over 4 months)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Usual care (verbal advice and provision of leaflets over one session)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Rehabilitation outdoor mobility intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 506
Study: 19087011

Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 93
Study: 17169012

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) 4 g solution (0.1 g/ml) infused over 30 minutes
Number of subjects: 573

Group type: COMPARATOR
Intervention: Isotonic 0.9% saline (placebo)
Number of subjects: 573
Study: 15898475

Group type: EXPERIMENTAL
Intervention: Individual behavioral skills training in conjunction with in situ training
Number of subjects: 13
Study: 11604346

Group type: EXPERIMENTAL
Intervention: On-pump/beating-heart surgery (Group I)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional CABG (Group II)
Number of subjects: 156
Study: 10077917

Group type: EXPERIMENTAL
Intervention: Nondirect electrochemical oxidation of blood and internal laser irradiation of blood using He‐Nd laser
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional intensive therapy
Number of subjects: 38
Study: 8046529

Group type: EXPERIMENTAL
Intervention: Long form scale (lower bound '< 1 out of 1,000,000')
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Short form scale (lower bound '< 1 out of 1,000')
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Age (older patients)
Number of subjects: 210
Study: 3292761

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both Ioxaglate and Iopamidol
Number of subjects: 100
Study: 30841863

Group type: EXPERIMENTAL
Intervention: Urea reduction ratio (URR) ≥0.67
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urea reduction ratio (URR)
Number of subjects: 0
Study: 28412986

Group type: EXPERIMENTAL
Intervention: CGA (600 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (0 mg CGA)
Number of subjects: 9
Study: 25850706

Group type: EXPERIMENTAL
Intervention: Donor corneas stored ≤7 days
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Donor corneas stored 8 to 14 days
Number of subjects: 1090
Study: 24112419

Group type: EXPERIMENTAL
Intervention: Commercially-constructed cookstove (Envirofit G3300/G3355)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Locally-constructed cookstove
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional open-fire design cookstoves (initial observational period)
Number of subjects: 120
Study: 21106920

Group type: EXPERIMENTAL
Intervention: bioprocessed bread
Number of subjects: 8

Group type: COMPARATOR
Intervention: control bread
Number of subjects: 8
Study: 19519311

Group type: EXPERIMENTAL
Intervention: 24g Sprotte atraumatic needle
Number of subjects: 63
Study: 16461168

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment including high-velocity and low-amplitude manipulation, proprioceptive neuromuscular facilitation, ischemic compression of myofascial trigger points, and spinal rehabilitation exercises.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 41
Study: 14767084

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFX) at a dose of 40 mg/kg subcutaneously, 5 days/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral deferiprone (L1) at a dose of 75 mg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of daily L1 at a dose of 75 mg/kg/day and DFX at a dose of 40 mg/kg/day two times per week
Number of subjects: 30
Study: 11577795

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with gabexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic antibacterials (carbapenems and quinolones)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic antifungal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy focusing on suppression of pro-inflammatory cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 0
Study: 9285295

Group type: EXPERIMENTAL
Intervention: IFN-beta 1b (Betaseron) treatment
Number of subjects: 0
Study: 8123056

Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2 and 65% O2 for 30 seconds
Number of subjects: 61

Group type: COMPARATOR
Intervention: Increased airway resistance (breathing through a valve reducing airway diameter)
Number of subjects: 61
Study: 3779921

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (152 patients) or intracoronary streptokinase preceded by intravenous streptokinase (117 patients)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional treatment (264 patients)
Number of subjects: 533
Study: 30550344

Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 80

Group type: COMPARATOR
Intervention: BIAsp30
Number of subjects: 80
Study: 28124799

Group type: EXPERIMENTAL
Intervention: Social skills training (8 weekly 2-hour sessions including cooperation, assertion, social cognitive problem solving strategies, role playing, games, and arts and crafts)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Attention placebo control (games and arts and crafts only)
Number of subjects: 91
Study: 24720731

Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (saline) administration
Number of subjects: 27
Study: 24347577

Group type: EXPERIMENTAL
Intervention: Caudate-putaminal transplantation of fetal striatal tissue
Number of subjects: 26

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 26
Study: 22151469

Group type: EXPERIMENTAL
Intervention: Urgent carotid endarterectomy (within 48 hours)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy (operated between 48 hours and 15 days after onset of symptoms)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Urgent carotid endarterectomy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Urgent carotid endarterectomy and Delayed carotid endarterectomy
Number of subjects: 456
Study: 19222764

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg intravenous bolus followed by continuous infusion of 20 microg kg(‐1) h(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 18
Study: 17559748

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15337176

Group type: EXPERIMENTAL
Intervention: High laser scan resolution (30,000 laser scan points and more)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low laser scan resolution (6000 laser scan points and less)
Number of subjects: 12
Study: 11702663

Group type: EXPERIMENTAL
Intervention: NAT2 polymorphism in recurrence group (n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: NAT2 polymorphism in control group (n=52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: NAT2 heterogeneity type in recurrence group (n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: NAT2 heterogeneity type in control group (n=52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Wild-type NAT2 (Wt/Wt)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: M*/M* genotype
Number of subjects: 104
Study: 8016770

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 500 micrograms four times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 1000 micrograms four times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 1500 micrograms four times daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2659290

Group type: EXPERIMENTAL
Intervention: Aztreonam + Clindamycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Tobramycin + Clindamycin
Number of subjects: 156
Study: 4938522

Group type: EXPERIMENTAL
Intervention: Conventional premedication (pethidine, promethazine, and atropine)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neuroleptanalgesia (droperidol and phenoperidine)
Number of subjects: 70
Study: 31609072

Group type: EXPERIMENTAL
Intervention: Avocatin B (AvoB) 50 mg per day for 60 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avocatin B (AvoB) 200 mg per day for 60 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study: 28366507

Group type: EXPERIMENTAL
Intervention: Structured elaborative feedback in clinical dental skills teaching
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no elaborative feedback)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Structured elaborative feedback
Number of subjects: 60
Study: 25340383

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Maximal medical therapy
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Maximal medical therapy plus LVRS
Number of subjects: 1218
Study: 23595135

Group type: EXPERIMENTAL
Intervention: SYN (synbiotic supplementation)
Number of subjects: 17

Group type: COMPARATOR
Intervention: PLA (placebo with maltodextrin)
Number of subjects: 17
Study: 21380990

Group type: EXPERIMENTAL
Intervention: Daily oral micronized progesterone (MP) 400 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19343972

Group type: EXPERIMENTAL
Intervention: Microforceps
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vitrector
Number of subjects: 28
Study: 16909322

Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership (NFP) home visiting intervention
Number of subjects: 111